Effects of GYDENPHY caspules on streptozotocin-induced type 1 diabetic in Swiss mouse model

2021 ◽  
Vol 25 (2) ◽  
pp. 24-32
Author(s):  
Trinh Thach Thi Nguyen ◽  
Duy Tuan Nguyen ◽  
Thanh Ha Tuan Nguyen ◽  
Thi Huong Lan Do ◽  
Hoang Ngan Nguyen
Keyword(s):  
Blood Glucose ◽  
Mouse Model ◽  
Glucose Concentration ◽  
Blood Glucose Concentration ◽  
Insulin Injection ◽  
Swiss Mouse ◽  
Hypoglycemic Effect ◽  
Control Group ◽  
Water Control

Objective: Evaluation the hypoglycemic effect of Gydenphy capsules on Streptozotocin-induced type 1 diabetic in Swiss mouse model. Methods: The type 1 diabetic model was established by intraperitoneal injections of Streptozocin 150mg/kg in Swiss mouse. Then, the Gydenphy were orally administered daily at a dose of 576 mg/kg/day or 1152 mg/kg/day in 10 days. Blood glucose concentration in the Gydenphy oral groups with that of water control group and the intraperitoneal insulin injection group was compared. Results: Blood glucose concentration in the groups using Gydenphy (dose576 mg/kg/24h and dose 1152 mg/kg/24h) significal decreased compared to the distilled water group at (p <0.05 at the time of 4 hours, 8 hours; p <0.01 at the time of 3, 10 days). The hypoglycemic effect of Gydenphy at 576mg/kg/day and 1152 mg/kg/day at 4 hours, 8 hours and 3 days were inferior to insulin 0.1 UI/kg/day for glycemic control. However, the hypoglycemic effect ofGydenphy were equivalent to insulin after 10 consecutive days on treatment. Conclusion: Gydenphy capsules have hypoglycemic effects onStreptozotocin-induced type 1 diabetes in Swiss mouse model.

Ononis natrix L. Lowers the Blood Glucose Concentration in Wistar Rats with Streptozotocin-induced Diabetes Mellitus

2020 ◽  
Vol 20 ◽  
Author(s):  
Baker F. Mubideen ◽  
Ala-Aldeen Ahmad Al-Serhan ◽  
Justin Z. Amarin ◽  
Arwa Al-Dweikat ◽  
Ra'ad Z. Al-Muhaisen ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Concentration ◽  
Wistar Rats ◽  
Blood Glucose Concentration ◽  
Positive Control ◽  
Negative Control ◽  
Control Group ◽  
High Dose ◽  
Dose Treatment ◽  
Streptozotocin Induced Diabetes

Background: Practitioners of traditional medicine use the decoction of Ononis natrix L. to treat hyperglycemia. The literature offers no evidence to support the use. Objective: To investigate the effect of the decoction of Ononis natrix L. on the blood glucose concentration in Wistar rats (Rattus norvegicus) with streptozotocin-induced diabetes mellitus. Methods: We obtained 35 Wistar rats from the animal colony of The University of Jordan School of Medicine. We induced diabetes by a single intraperitoneal injection of streptozotocin (60 mg/kg body weight) and 23 rats (66%) survived to allocation. We randomly assigned the rats to one of four groups: negative control (1% Tween 80 in distilled water), positive control (100 mg/kg metformin), high-dose treatment (7.5 mL of the decoction), and low-dose treatment (3.5 mL of the decoc-tion). We administered the doses twice daily by oral gavage for two weeks and measured the tail-blood glucose concentration twice daily, once before the first dose and another time after the second dose. We used linear mixed-effects regression to model the change in blood glucose concentration as a function of the experimentation groups, with adjustments for pseu-doreplication and temporal variation. Results: The estimated mean change was 1 mmol/L (−30 to 31 mmol/L) for the negative control group, −26 mmol/L (−56 to 5 mmol/L) for the positive control group, −75 mmol/L (−108 to −42) for the low-dose treatment group, and −82 mmol/L (−111 to −53 mmol/L) for the high-dose treatment group. Conclusion: In conclusion, we demonstrate, for the first time, the hypoglycemic effect of Ononis natrix L. in an animal model of diabetes.

Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes?

2011 ◽  
Vol 89 (7) ◽  
pp. 477-484 ◽  
Author(s):  
Dairo A. Rendon ◽  
Jose A. Alvarez-Bustamante
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Mitochondrial Dysfunction ◽  
Glucose Concentration ◽  
Alloxan Diabetes ◽  
Blood Glucose Concentration ◽  
Diabetic State ◽  
Acceptable Model

Alloxan and oxidative stress, which have been detected in livers of laboratory animals shortly after in vivo alloxan administration, cause in vitro mitochondrial dysfunction, thus questioning alloxan diabetes as an acceptable model for type 1 diabetes, a model that cannot legitimately be used to investigate mitochondrial metabolism in a diabetic state. In the current study, the blood glucose concentration increased in the drug-treated group of Sprague–Dawley rats (compared with the placebo group) 45 or 60 min after alloxan treatment, whereas at 30 min the blood glucose concentration was unchanged. State 4, state 3, respiratory control, efficiency of oxidative phosphorylation, and mitochondrial ATP synthase activity, assayed using glutamate plus malate, pyruvate plus malate, or succinate as a substrate, were not negatively altered during the entire study. These results indicated that early increases of blood glucose concentration, after in vivo alloxan administration, did not lead to liver mitochondrial dysfunction, suggesting that alloxan diabetes can be used for the study of liver mitochondrial respiration in a diabetic state.

scholarly journals Pre-Exercise Blood Glucose Levels Determine the Amount of Orally Administered Carbohydrates during Physical Exercise in Individuals with Type 1 Diabetes—A Randomized Cross-Over Trial

Nutrients ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 1287 ◽  
Author(s):  
Othmar Moser ◽  
Max L. Eckstein ◽  
Alexander Mueller ◽  
Philipp Birnbaumer ◽  
Felix Aberer ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glucose Concentration ◽  
Basal Insulin ◽  
Blood Glucose Concentration ◽  
Insulin Dose ◽  
Moderate Intensity ◽  
Rank Test ◽  
The Impact

The aim of the study was to assess the amount of orally administered carbohydrates needed to maintain euglycemia during moderate-intensity exercise in individuals with type 1 diabetes. Nine participants with type 1 diabetes (four women, age 32.1 ± 9.0 years, BMI 25.5 ± 3.9 kg/m2, HbA1c 55 ± 7 mmol/mol (7.2 ± 0.6%)) on insulin Degludec were randomized to cycle for 55 min at moderate intensity (63 ± 7% VO2peak) for five consecutive days on either 75% or 100% of their regular basal insulin dose. The impact of pre-exercise blood glucose concentration on the carbohydrate requirement was analyzed by one-way ANOVA stratified for pre-exercise blood glucose quartiles. The effect of the basal insulin dose on the amount of orally administered carbohydrates was evaluated by Wilcoxon matched-pairs signed-rank test. The amount of orally administered carbohydrates during the continuous exercise sessions was similar for both trial arms (75% or 100% basal insulin) with median [IQR] of 36 g (9–62 g) and 36 g (9–66 g) (p = 0.78). The amount of orally administered carbohydrates was determined by pre-exercise blood glucose concentration for both trial arms (p = 0.03). Our study elucidated the importance of pre-exercise glucose concentration related orally administered carbohydrates to maintain euglycemia during exercise in individuals with type 1 diabetes.

Sign in / Sign up

Export Citation Format

Share Document